# A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct06257680/  
OnCo record `nct06257680` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ReT01 ACT run by Beijing Xunsheng Biomedical Research Co., Ltd., now recruiting.

## Summary

A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors is a phase 1 interventional study registered as NCT06257680 by Beijing Xunsheng Biomedical Research Co., Ltd., with 15 participants planned, started 2024-04-08. Conditions recorded: Advanced Solid Tumor. Interventions recorded: ReT01 ACT.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06257680
- Phase: 1
- Setting: A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors
- Sponsor: Beijing Xunsheng Biomedical Research Co., Ltd.
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT06257680: https://clinicaltrials.gov/study/NCT06257680

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ReT01 ACT](https://onco.cc/drugs/ret01/)
- companies: [Beijing Xunsheng Biomedical Research](https://onco.cc/companies/beijing-xunsheng-biomedical/)

---
JSON: https://onco.cc/api/v1/entities/nct06257680.json